Table 2.
The results of the sensitivity analysis in the main analysis
| Factor | Number of patients | Stratified log-rank test | Stratified hazard ratio (95% CI) |
|---|---|---|---|
| Whole main analysis population | n = 410 | p = 0.0040 | 1.337 (1.096–1.631) |
| Subset | |||
| Age < 75 years | n = 295 | p = 0.0044 | 1.406 (1.111–1.779) |
| BMI < 30 kg/m2 | n = 393 | p = 0.0029 | 1.359 (1.110–1.665) |
| No medical history | n = 217 | p = 0.0025 | 1.569 (1.169–2.104) |
| No coexisting diseases | n = 215 | p = 0.0229 | 1.376 (1.044–1.814) |
| No surgery-related complications | n = 348 | p = 0.0101 | 1.327 (1.069–1.647) |
| Average daily dose until defecation ≥ 10 g | n = 369 | p = 0.0019 | 1.395 (1.130–1.723) |
Values represent the number of patients, p values of stratified log-rank tests, and stratified hazard ratios in the Daikenchuto-treated versus placebo-treated groups, along with 95% confidence intervals for the whole subgroup population and all subpopulations used in the sensitivity analysis
BMI body mass index, CI confidence interval